Lowe Brockenbrough & Co. Inc. Has $4.22 Million Holdings in Pfizer Inc. (NYSE:PFE)

Lowe Brockenbrough & Co. Inc. lessened its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 39.4% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 158,978 shares of the biopharmaceutical company's stock after selling 103,314 shares during the quarter. Lowe Brockenbrough & Co. Inc.'s holdings in Pfizer were worth $4,218,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in PFE. Retirement Wealth Solutions LLC purchased a new position in Pfizer in the 4th quarter valued at about $26,000. Rialto Wealth Management LLC purchased a new position in shares of Pfizer during the 4th quarter worth $26,000. Kohmann Bosshard Financial Services LLC purchased a new stake in shares of Pfizer in the fourth quarter valued at $28,000. Noble Wealth Management PBC acquired a new position in Pfizer in the fourth quarter valued at $31,000. Finally, Curio Wealth LLC purchased a new position in Pfizer during the fourth quarter worth about $32,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Price Performance

Shares of PFE stock traded down $0.15 during midday trading on Monday, reaching $26.13. 37,863,216 shares of the company were exchanged, compared to its average volume of 36,651,022. The company's 50 day moving average price is $26.17 and its two-hundred day moving average price is $27.04. Pfizer Inc. has a 12 month low of $24.48 and a 12 month high of $31.54. The company has a market cap of $148.21 billion, a P/E ratio of 18.53, a PEG ratio of 0.64 and a beta of 0.61. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00.

Remove Ads

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.15. The company had revenue of $17.76 billion for the quarter, compared to analysts' expectations of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm's revenue was up 24.7% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.10 earnings per share. On average, sell-side analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Insider Buying and Selling

In other news, Director Ronald E. Blaylock bought 19,457 shares of the firm's stock in a transaction on Thursday, February 13th. The stock was bought at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the acquisition, the director now directly owns 27,707 shares in the company, valued at $710,684.55. This represents a 235.84 % increase in their position. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. 0.06% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on PFE shares. Hsbc Global Res upgraded shares of Pfizer to a "strong-buy" rating in a report on Monday, March 10th. UBS Group decreased their price target on Pfizer from $31.00 to $29.00 and set a "neutral" rating for the company in a report on Wednesday, January 8th. Guggenheim restated a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. Citigroup reduced their target price on Pfizer from $30.00 to $29.00 and set a "neutral" rating for the company in a research note on Tuesday, January 28th. Finally, Bank of America restated a "neutral" rating and issued a $29.00 price target on shares of Pfizer in a research note on Tuesday, December 10th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating, six have issued a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $31.92.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.